These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27493132)

  • 1. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
    Ahrén B; Hirsch IB; Pieber TR; Mathieu C; Gómez-Peralta F; Hansen TK; Philotheou A; Birch S; Christiansen E; Jensen TJ; Buse JB;
    Diabetes Care; 2016 Oct; 39(10):1693-701. PubMed ID: 27493132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.
    Hulst AH; Visscher MJ; Godfried MB; Thiel B; Gerritse BM; Scohy TV; Bouwman RA; Willemsen MGA; Hollmann MW; Preckel B; DeVries JH; Hermanides J;
    Diabetes Obes Metab; 2020 Apr; 22(4):557-565. PubMed ID: 31749275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost.
    Houda SM; Toshihiro U; Yuriko Y; Hiroyuki O; Reie M; Anna S; Masafumi M
    Diabetol Int; 2020 Jan; 11(1):49-56. PubMed ID: 31950004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes.
    Tonoike M; Chujo D; Noda M
    Endocrinol Diabetes Metab; 2019 Jan; 2(1):e00043. PubMed ID: 30815572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
    Mathieu C; Zinman B; Hemmingsson JU; Woo V; Colman P; Christiansen E; Linder M; Bode B;
    Diabetes Care; 2016 Oct; 39(10):1702-10. PubMed ID: 27506222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
    Hadjadj S; Rosenstock J; Meinicke T; Woerle HJ; Broedl UC
    Diabetes Care; 2016 Oct; 39(10):1718-28. PubMed ID: 27493136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Marso SP; Bain SC; Consoli A; Eliaschewitz FG; Jódar E; Leiter LA; Lingvay I; Rosenstock J; Seufert J; Warren ML; Woo V; Hansen O; Holst AG; Pettersson J; Vilsbøll T;
    N Engl J Med; 2016 Nov; 375(19):1834-1844. PubMed ID: 27633186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Tonneijck L; Smits MM; Muskiet MH; Hoekstra T; Kramer MH; Danser AH; Ter Wee PM; Diamant M; Joles JA; van Raalte DH
    Diabetes Care; 2016 Nov; 39(11):2042-2050. PubMed ID: 27585605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
    Dejgaard TF; Johansen NB; Frandsen CS; Asmar A; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Diabetes Obes Metab; 2017 May; 19(5):734-738. PubMed ID: 27935240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.
    Kalra S
    Diabetes Ther; 2016 Dec; 7(4):601-609. PubMed ID: 27613064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
    Henry RR; Klein EJ; Han J; Iqbal N
    Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Wang W; Liu H; Xiao S; Liu S; Li X; Yu P
    Diabetes Ther; 2017 Aug; 8(4):727-738. PubMed ID: 28616805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
    Heise T; Mathieu C
    Diabetes Obes Metab; 2017 Jan; 19(1):3-12. PubMed ID: 27593206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study.
    Lak V; Svensson AM; Miftaraj M; Franzén S; Eliasson B
    Diabetes Ther; 2016 Sep; 7(3):561-73. PubMed ID: 27517679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.